Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma

The primary objective of this trial is to evaluate the safety and tolerability of the tumor neoantigen vaccine (SarcVac) in combination with a PD-1 antibody, with or without tumor-specific lymphocytes, in patients with advanced bone and soft tissue sarcoma who have failed first-line treatment. The secondary objectives are to assess the preliminary efficacy of SarcVac combined with a PD-1 antibody, with or without tumor-specific lymphocytes, in these patients and to evaluate whether the vaccine's efficacy demonstrates dose dependency.

Trial Details

NCT ID
NCT07648069
Phase
PHASE1
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
Osteosarcoma Sarcoma
Interventions
  • Neoantigen vaccine + specific lymphocytes + anti-PD1 antibody
  • Neoantigen vaccine + anti-PD1 antibody
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Before any procedures related to the research program, including screening and evaluation stage, signed informed consent.
  • Age≥18 years old, and≤70 years old ;
  • Pathologically diagnosed as solid tumors, including bone or soft tissue sarcoma, and staging for advanced or unresectable patients ;
  • Patients with first-line treatment failure ;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →